Solbec granted patent
Thursday, 29 September, 2005
Solbec Pharmaceuticals (ASX:SBP) has been granted an Australian patent giving the company the monopoly right to prevent others from isolating the rhamnose binding protein receptor of its lead compound Coramsine.
Last month Solbec was granted a US patent based on the same inventive material. The RBP receptor is over-expressed in mammalian cancer cells, but not in healthy cells, and explains why Solbec's Coramsine is selective in targeting cancer cells.
The term of the patent runs until February 2023.
Research project to produce fish-free omega-3
SCU researchers are investigating how to grow omega-3-producing microorganisms more cheaply...
Biodegradable smart patch can detect and treat blood clots
Researchers have developed a biodegradable smart patch that detects pressure changes and releases...
Biotech manufacturing facility opens in Brisbane
ENTRI, a purpose-built multimodal facility which will enable biotech companies to manufacture...
